Dexcom launches generative AI platform for Stelo users
The Dexcom logo is seen on a smartphone screen and in the background. Pavlo Gonchar | SOPA Images | Light…
business news
What a government shutdown could mean for air travel
A lone traveler passes through a nearly deserted TSA security screening area at Orlando International Airport ahead of the landfall…
Suki and Google Cloud Expand Healthcare Technology Partnership
Healthcare artificial intelligence startup Suki on Wednesday announced a new collaboration with Google cloud as part of its push to…
Merck signs weight loss pills licensing agreement with Hansoh Pharma
Exterior view of the entrance to Merck headquarters on February 5, 2024 in Rahway, New Jersey. Spencer Platt | fake…
Eli Lilly's Zepbound Weight Loss Drug No Longer in Shortage
An injectable pen of Zepbound, Eli Lilly's weight loss drug, is on display in New York City on December 11,…
American Homeowners Are Wasting More Space Than Ever
Tim Kitchen | The Image Bank | fake images There may not be many homes for sale these days, but…
Ozempic faces scrutiny over possible risk of eye condition
A box of Ozempic manufactured by Novo Nordisk is seen in a pharmacy in London, Britain, March 8, 2024. Hollie…
Japan's Honda and Nissan would begin merger talks
Makoto Uchida, president and CEO of Nissan Motor, and Toshihiro Mibe, president and CEO of Honda Motor, attend their joint…
Family offices face hidden risks when making direct investments
A version of this article first appeared in CNBC's Inside Wealth newsletter with Robert Frank, a weekly guide for high-net-worth…
We're adding to our position in a stock that just got some big support from Wall Street.
Shortly after the bell rings, we will buy 300 shares of Bristol Myers Squibb at approximately $56.50. Following the deal,…